Bendamustine With or Without Cyclophosphamide in Preventing GVHD in Patients Undergoing Stem Cell Transplant
Hematopoietic and Lymphoid System Neoplasm

About this trial
This is an interventional treatment trial for Hematopoietic and Lymphoid System Neoplasm
Eligibility Criteria
Inclusion Criteria:
- Patient with hematologic malignancies.
- Donor: Mismatched or haplo-identical.
- Zubrod performance 0 to 2 or Karnofsky of at least 60.
- Creatinine less than or equal to 1.6 mg/dL and creatinine clearance >= 30 ml/min. Creatine clearance will be calculated using the Cockcroft-Gault equation. (at time of study entry)
- Total bilirubin less than < 1.5 x upper limit of normal (UNL). (at time of study entry)
- Serum glutamate pyruvate transaminase (SGPT) < 2.5 x ULN. (at time of study entry)
- Ejection fraction >= 40%. (at time of study entry)
- Forced expiratory volume in one second (FEV1) >= 40%. (at time of study entry)
- Forced vital capacity (FVC) >= 40%. (at time of study entry)
- Diffusion capacity of the lung for carbon monoxide (DLCO) >= 40%. (at time of study entry)
Exclusion Criteria:
- Pregnant or nursing women.
- Known to be human immunodeficiency virus (HIV) positive.
- Active and uncontrolled disease/infection.
- Unable or unwilling to sign consent.
- Current active hepatic or biliary disease (with exception of Gilbert's syndrome).
- Active hepatitis B or C.
- Toxicities (grade > 1) unresolved from prior treatment (including chemotherapy, targeted therapy, immunotherapy, experimental agents radiation, or surgery.
- Patients with standard risk acute leukemia in first complete remission and patients with chronic myeloid leukemia in first chronic will be excluded during escalated phase.
Sites / Locations
- M D Anderson Cancer CenterRecruiting
Arms of the Study
Arm 1
Arm 2
Experimental
Experimental
Schedule I (non-lymphoma)
Schedule II (lymphoid malignancies)
Patients receive fludarabine IV over 1 hour on days -5 to -2, melphalan IV over 30 minutes on days -5 and -4, and undergo TBI on day -1 and stem cell transplantation IV over 2-6 hours on day 0. Depending on when the trial was joined, patients receive cyclophosphamide IV over 3 hours or bendamustine IV over 30-60 minutes or cyclophosphamide IV over 3 hours and bendamustine IV over 30-60 minutes on day 3. Patients also receive bendamustine IV over 30-60 minutes on day 4. Beginning day 5, patients receive tacrolimus IV followed by PO QD or BID for 6 months and mycophenolate mofetil PO TID until day 100. Beginning day 7, patients receive filgrastim-sndz SC QD until blood cell levels return to normal.
Patients receive fludarabine IV over 1 hour, bendamustine IV over 30-60 minutes on days -5 to -3 and undergo TBI on day -1 and stem cell transplantation over 2-6 hours on day 0. Depending on when the trial was joined, patients receive cyclophosphamide IV over 3 hours or bendamustine IV over 30-60 minutes or cyclophosphamide IV over 3 hours and bendamustine IV over 30-60 minutes on day 3. Patients also receive bendamustine IV over 30-60 minutes on day 4. Beginning day 5, patients receive tacrolimus IV followed by PO QD or BID for 6 months and mycophenolate mofetil PO TID until day 100. Beginning day 7, patients receive filgrastim-sndz SC QD until blood cell levels return to normal. CD20+ patients receive rituximab IV over 4-6 hours on days -13, -6, 1, and 8.